Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $310,483.18 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 5,738 shares of the company’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $54.11, for a total value of $310,483.18. Following the completion of the sale, the director now directly owns 186,541 shares in the company, valued at $10,093,733.51. This trade represents a 2.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mona Ashiya also recently made the following trade(s):

• On Friday, March 21st, Mona Ashiya sold 10,011 shares of Disc Medicine stock. The stock was sold at an average price of $54.00, for a total transaction of $540,594.00.
• On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The stock was sold at an average price of $54.02, for a total transaction of $2,142,217.12.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total value of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The stock was sold at an average price of $54.29, for a total value of $10,974,506.34.

Disc Medicine Stock Performance

Disc Medicine stock traded down $0.30 during midday trading on Wednesday, reaching $52.49. The stock had a trading volume of 205,112 shares, compared to its average volume of 359,263. The stock’s 50-day simple moving average is $55.06 and its 200 day simple moving average is $56.15. Disc Medicine, Inc. has a twelve month low of $25.60 and a twelve month high of $68.73. The stock has a market capitalization of $1.81 billion, a PE ratio of -13.19 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.08. Equities analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently bought and sold shares of the business. Sterling Capital Management LLC raised its stake in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after acquiring an additional 503 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Disc Medicine in the 4th quarter valued at $40,000. Tower Research Capital LLC TRC increased its holdings in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after purchasing an additional 266 shares in the last quarter. Quest Partners LLC purchased a new position in Disc Medicine in the third quarter valued at about $131,000. Finally, Quantbot Technologies LP acquired a new position in shares of Disc Medicine during the third quarter worth about $146,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on IRON. Morgan Stanley reaffirmed an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Friday, March 7th. Wedbush reiterated an “outperform” rating and set a $90.00 price target (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Cantor Fitzgerald upped their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. Scotiabank raised their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 3rd. Finally, Stifel Nicolaus boosted their price target on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a report on Friday, January 24th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $93.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.